Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ: TCRX )

2.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Transition of Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics: Q1 Earnings Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Via Benzinga
Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting the day off right with a breakdown of the biggest pre-market stock movers worth reading about on Wednesday! 
Via InvestorPlace
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on target... 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Closing of Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 10%; Here Are 20 Stocks Moving Premarket
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares rose 206.7% to $0.2350 in pre-market trading after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter... 
Via Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for a look at the biggest pre-market stock movers on Tuesday morning with all the details traders need to know about! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for another dive into the biggest pre-market stock movers as we check out what's happening this morning on Friday! 
Via InvestorPlace
TScan Therapeutics Announces Pricing of $140 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Launch of Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients
TScan Therapeutics Inc (NASDAQ: TCRX) announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.